Multi-organ system and quality-of-life benefits sustained through five years of treatment – 82% response rate for the ...
Company Continuing Limited Over-Enrollment Activities to Account for Attrition and Support Robust Modified Intent-to-Treat, End-of-Treatment and Exploratory Analyses POTOMAC, MD / ACCESS Newswire / ...
Prediction of Treatment Efficacy in Locally Advanced Rectal Cancer Using a Clinical and Magnetic Resonance Imaging–Based Radiomics-Immunological Model for Total Neoadjuvant Therapy Fifty patients were ...
Energy utility consultants for the Public Services Commission have labeled the Water and Power Authority’s Phase 2 Wärtsilä ...
OpenAI is preparing what CNBC’s Joe Kernen, citing Financial Times reporting, called “The biggest update to ChatGPT since the ...
AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced a significant milestone in its pancreatic cancer development program, with enrollment of the final subject, barring ...
Basel, June 11, 2026 - Novartis announced today that the biomarker cohort of the FORTITUDE Phase I/II study of del-brax met ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results